Lunai Bioworks (NASDAQ: LNAI) announced the formation of the Pathfinder Consortium, a national academic-industry alliance designed to accelerate development of chemical countermeasures for battlefield and terrorism threats. The consortium aims to consolidate U.S. chemical warfare preparedness resources into a unified infrastructure.

The company stated that validated countermeasures are typically procured by the U.S. government for national stockpiling programs ranging between $400 million and $1.2 billion per program. Through its wholly owned subsidiary BioSymetrics, Lunai plans to pursue funding from BARDA, Department of Defense, and Homeland Security programs.

The consortium's development model targets a three-year regulatory pathway, which includes demonstrating efficacy in yeast and cell-based systems, validating therapeutic effects in FDA-recognized zebrafish models, completing two confirmatory animal studies, and conducting a 50-person Phase I safety study.

"Chemical defense cannot operate on a decade-long pharmaceutical clock," said David Weinstein, CEO of Lunai Bioworks. "The regulatory framework allows for speed, and Pathfinder is designed to execute within that accelerated pathway."

The consortium includes collaboration with researchers from Brigham and Women's Hospital, Harvard Medical School, University of Colorado, University of Utah, and Purdue University. Dr. Vik Bebarta, a Colonel in the U.S. Air Force Reserve, is among the participants.

Pathfinder leverages BioSymetrics' AI-enabled phenotypic platform, which integrates machine learning analytics with high-throughput vertebrate screening to identify toxicologic signatures and therapeutic leads. The company noted that existing FDA-approved drugs may be repurposed, potentially reducing development timelines further.

Lunai Bioworks is an AI-enabled biotechnology company focused on rapid in vivo phenotypic drug discovery across CNS and biodefense applications.